Number needed to treat and cost per responder for biologic therapies for the treatment of moderate to severe psoriasis - 16/03/14
Richard G. Langley, Dalhousie University, Halifax, Canada; James Signorovitch, Analysis Group, Inc, Boston, MA, United States; Ke Wang, Global Health Economics and Outcomes Research, AbbVie, North Chicago, IL, United States; Keith A. Betts, Analysis Group, Inc, Boston, MA, United States; Murali Sundaram, Global Health Economics and Outcomes Research, AbbVie, North Chicago, IL, United States; Parvez Mulani, Global Health Economics and Outcomes Research, AbbVie, North Chicago, IL, United States; Sherry Yan, Analysis Group, Inc, Boston, MA, United States
Le texte complet de cet article est disponible en PDF. Design, study conduct, and financial support for the study were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the abstract. All authors contributed to the development of the publication and maintained control over the final content. |
Vol 70 - N° 5S1
P. AB2 - mai 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?